Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Sabrina Gloria Giulia Testoni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0042-2583; OpenAlex author ID A5018251861. Sources: OpenAlex.

Their work

Papers
22 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2019: 1 paper · 2020: 3 papers · 2021: 7 papers · 2022: 3 papers · 2023: 4 papers · 2024: 2 papers · 2025: 2 papers

Papers 22

  1. From classical approaches to artificial intelligence, old and new tools for PDAC risk stratification and prediction. Co-author DOI 10.1016/j.semcancer.2025.03.004↗
  2. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  3. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  4. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  5. Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. Co-author DOI 10.1002/deo2.152↗
  6. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  7. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  8. Immunomodulatory Effects of Endoscopic Ultrasound-Guided Thermal Ablation in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15143704↗
  9. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  10. B-Lymphocytes in the Pathophysiology of Pancreatic Adenocarcinoma. First author DOI 10.3389/fimmu.2022.867902↗
  11. EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic ductal adenocarcinoma: A case-control stud… Co-author DOI 10.4103/eus-d-21-00200↗
  12. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  13. Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. Co-author DOI 10.1007/s00280-020-04190-1↗
  14. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  15. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  16. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  17. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  18. Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomi… Co-author DOI 10.3390/cancers13184512↗
  19. Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer. Co-author DOI 10.1055/a-1221-9879↗
  20. RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of Molecular Features. Co-author DOI 10.3390/cells9122561↗
  21. Systematic review of endoscopy ultrasound-guided thermal ablation treatment for pancreatic cancer. First author DOI 10.4103/eus.eus_74_19↗
  22. New era for pancreatic endoscopic ultrasound: From imaging to molecular pathology of pancreatic cancer. First author DOI 10.4251/wjgo.v11.i11.933↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paolo Giorgio Arcidiacono · 8 shared papers, 2019–2023 · strength 0.98
  2. Michele Reni · 8 shared papers, 2019–2023 · strength 0.93
  3. Gabriele Capurso · 8 shared papers, 2019–2023 · strength 0.91
  4. Maria Chiara Petrone · 7 shared papers, 2019–2023 · strength 0.81
  5. Massimo Falconi · 7 shared papers, 2019–2023 · strength 0.81
  6. Emanuel Della‐Torre · 5 shared papers, 2020–2023 · strength 0.74
  7. Gemma Rossi · 6 shared papers, 2020–2023 · strength 0.69
  8. Francesco DE COBELLI · 5 shared papers, 2020–2023 · strength 0.62
  9. Claudio Doglioni · 5 shared papers, 2019–2023 · strength 0.56
  10. Lívia Archibugi · 5 shared papers, 2019–2023 · strength 0.52
  11. Claudia Minici · 2 shared papers, 2022–2023 · strength 0.41
  12. Matteo Tacelli · 2 shared papers, 2023–2025 · strength 0.36
  13. Giulia Peduzzi · 2 shared papers, 2022–2025 · strength 0.32
  14. Daniele Campa · 2 shared papers, 2022–2025 · strength 0.32
  15. Manuel Gentiluomo · 2 shared papers, 2022–2025 · strength 0.32
  16. Giulio Belfiori · 2 shared papers, 2021–2023 · strength 0.25
  17. Gianpaolo Balzano · 2 shared papers, 2021–2022 · strength 0.24
  18. Giuseppe Vanella · 2 shared papers, 2022–2023 · strength 0.23
  19. Riccardo Farinella · 1 shared paper, 2025 · strength 0.22
  20. Ricardo Blázquez‐Encinas · 1 shared paper, 2025 · strength 0.22
  21. Eithne Costello · 1 shared paper, 2025 · strength 0.22
  22. Miriam Redegalli · 2 shared papers, 2019–2020 · strength 0.20
  23. ChristophF Dietrich · 1 shared paper, 2020 · strength 0.16
  24. Maria Pia Protti · 1 shared paper, 2023 · strength 0.14
  25. Lucia B. De Monte · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.